Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
NASDAQ Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Editas Medicine, Inc.
Editas Medicine Announces Second Quarter 2024 Results and Business Updates
August 07, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Second Quarter 2024 Results Conference Call and Corporate Update
July 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Reports New Safety and Efficacy Data from the RUBY Trial of Reni-cel in 18 Patients with Sickle Cell Disease, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces New Safety and Efficacy Data from the EdiTHAL Trial of Reni-cel in 7 Patients with Transfusion-dependent Beta Thalassemia, Presented at the European Hematology Association (EHA) Annual Congress
June 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of Reni-cel at the European Hematology Association 2024 Congress in June
May 14, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Preclinical Data Highlights Advancement of in vivo Gene Editing Medicine Technologies at the American Society of Gene and Cell Therapy Annual Meeting
May 10, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces First Quarter 2024 Results and Business Updates
May 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces First Quarter 2024 Results Conference Call and Upcoming Investor Events
May 02, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine and Bristol Myers Squibb Extend Alpha-Beta T Cell Collaboration
May 01, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
BMY
EDIT
Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting
April 22, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results and Business Updates
February 28, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Fourth Quarter and Full Year 2023 Results Conference Call and Upcoming Investor Events
February 21, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Participate in Upcoming Investor Conferences
January 31, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Highlights 2024 Anticipated Milestones and Strategic Priorities at the J.P. Morgan Healthcare Conference
January 08, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 03, 2024
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine and Vertex Pharmaceuticals Enter into Non-exclusive License Agreement for Cas9
December 13, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces New EDIT-301 Safety and Efficacy Data in 17 Patients, Presented Today at the American Society of Hematology (ASH) Annual Meeting and in a Company-sponsored Webinar
December 11, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Third Quarter 2023 Results and Business Updates
November 03, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine to Present Clinical Data from the RUBY and EdiTHAL Trials of EDIT-301 at the ASH 2023 Annual Meeting and in a Company-sponsored Webinar
November 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Third Quarter 2023 Results Conference Call and Upcoming Investor Events
October 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Granted FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for EDIT-301 for the Treatment of Severe Sickle Cell Disease
October 16, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Reports Inducement Grants to New Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Strengthens Executive Leadership Team with Appointment of Caren Deardorf as Chief Commercial and Strategy Officer
September 25, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Upcoming Investor Events
August 30, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Second Quarter 2023 Results and Business Updates
August 02, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine and Azzur Group Expand Partnership to Accelerate Editas’ Manufacturing Capabilities for Advancing the EDIT-301 Program Through Approval to Commercialization
July 27, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Second Quarter 2023 Results Conference Call and Corporate Update
July 26, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Strengthens Executive Leadership Team with Appointment of Linda C. Burkly, Ph.D., as Chief Scientific Officer
July 24, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Pricing of Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Editas Medicine Announces Offering of Common Stock
June 14, 2023
From
Editas Medicine, Inc.
Via
GlobeNewswire
Tickers
EDIT
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.